Collegium Pharmaceutical, Inc.
COLL
$27.27
$0.220.81%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -60.75% | -54.76% | 50.73% | 259.03% | 543.67% |
| Total Depreciation and Amortization | 59.35% | 12.37% | -7.54% | -7.44% | -7.45% |
| Total Amortization of Deferred Charges | -27.46% | -43.13% | -29.06% | -22.17% | -17.62% |
| Total Other Non-Cash Items | -143.41% | -49.53% | 107.67% | -91.06% | -34.51% |
| Change in Net Operating Assets | 899.67% | -824.44% | -105.56% | 77.41% | -108.93% |
| Cash from Operations | 15.42% | -112.16% | -32.41% | 123.83% | 10.57% |
| Capital Expenditure | -247.56% | -275.38% | -382.14% | -222.73% | 82.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 55.11% | 600.90% | 79.27% | -- | -- |
| Cash from Investing | 53.13% | -6,413.95% | 78.65% | -10,200.00% | -2,569.89% |
| Total Debt Issued | 88.30% | -- | -- | -- | -- |
| Total Debt Repaid | 64.77% | -259.18% | -72.48% | 71.99% | -83.33% |
| Issuance of Common Stock | -94.66% | 4.55% | 357.15% | 13.54% | -52.79% |
| Repurchase of Common Stock | -0.28% | 99.72% | -18,479.55% | -66.42% | -228.30% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -88.30% | -- | -- | -- | -- |
| Cash from Financing | 39.14% | 256.19% | -152.47% | -179.28% | -162.66% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 261.37% | -331.99% | -536.34% | -110.79% | -149.50% |